Select Publications
Journal articles
2021, 'Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey', Journal of the American Academy of Dermatology, 85, pp. 1161 - 1167, http://dx.doi.org/10.1016/j.jaad.2020.03.028
,2021, 'European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II', Journal of the European Academy of Dermatology and Venereology, 35, pp. 1926 - 1948, http://dx.doi.org/10.1111/jdv.17395
,2021, 'Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*', British Journal of Dermatology, 185, pp. 745 - 755, http://dx.doi.org/10.1111/bjd.20431
,2021, 'Assessment of skin of color and diversity and inclusion content of dermatologic published literature: An analysis and call to action', International Journal of Women's Dermatology, 7, pp. 391 - 397, http://dx.doi.org/10.1016/j.ijwd.2021.04.001
,2021, 'Embracing diversity in dermatology: Creation of a culture of inclusion in dermatologic publishing', International Journal of Women's Dermatology, 7, pp. 371 - 377, http://dx.doi.org/10.1016/j.ijwd.2021.08.001
,2021, 'European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I', Journal of the European Academy of Dermatology and Venereology, 35, pp. 1750 - 1764, http://dx.doi.org/10.1111/jdv.17397
,2021, 'Gdf6 knockdown in a family with multiple synostosis syndrome and speech impairment', Genes, 12, http://dx.doi.org/10.3390/genes12091354
,2021, 'Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey', Pediatric Dermatology, 38, pp. 1198 - 1201, http://dx.doi.org/10.1111/pde.14802
,2021, 'Pharmacist recommendations regarding topical steroid use may contradict the standard of care in atopic dermatitis: An international, cross-sectional study', JAAD International, 4, pp. 13 - 14, http://dx.doi.org/10.1016/j.jdin.2021.04.005
,2021, 'The impact of gender in mentor–mentee success: Results from the Women's Dermatologic Society Mentorship Survey', International Journal of Women's Dermatology, 7, pp. 398 - 402, http://dx.doi.org/10.1016/j.ijwd.2021.04.010
,2021, 'Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus', Frontiers in Medicine, 8, http://dx.doi.org/10.3389/fmed.2021.708071
,2021, 'Impact of COVID-19 on inpatient dermatology consults in an Australian tertiary hospital', Australasian Journal of Dermatology, 62, pp. 427 - 428, http://dx.doi.org/10.1111/ajd.13649
,2021, 'Are biosimilars for pemphigus safe?', Clinical and Experimental Dermatology, 46, pp. 942 - 943, http://dx.doi.org/10.1111/ced.14610
,2021, 'Individual patients’ risk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximab', Journal of the American Academy of Dermatology, 85, pp. e47 - e48, http://dx.doi.org/10.1016/j.jaad.2021.03.018
,2021, 'Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study', Journal of the European Academy of Dermatology and Venereology, 35, pp. 1562 - 1568, http://dx.doi.org/10.1111/jdv.17218
,2021, 'Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis', Journal of the American Academy of Dermatology, 85, pp. 1 - 14, http://dx.doi.org/10.1016/j.jaad.2020.11.076
,2021, 'Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy', Journal of the American Academy of Dermatology, 85, pp. 18 - 27, http://dx.doi.org/10.1016/j.jaad.2020.05.161
,2021, 'Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic', Journal of the European Academy of Dermatology and Venereology, 35, pp. e412 - e414, http://dx.doi.org/10.1111/jdv.17207
,2021, 'What instruments should we add to our toolbox for measuring the severity and control of eczema?', British Journal of Dermatology, 185, pp. 13 - 14, http://dx.doi.org/10.1111/bjd.20398
,2021, 'Intraepithelial autoimmune blistering dermatoses: Clinical features and diagnosis', Journal of the American Academy of Dermatology, 84, pp. 1507 - 1519, http://dx.doi.org/10.1016/j.jaad.2020.11.075
,2021, 'Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy', Journal of the American Academy of Dermatology, 84, pp. 1523 - 1537, http://dx.doi.org/10.1016/j.jaad.2021.02.073
,2021, 'The International Reach of the International Journal of Women's Dermatology and the Women's Dermatologic Society', International Journal of Women's Dermatology, 7, pp. 235 - 236, http://dx.doi.org/10.1016/j.ijwd.2021.05.004
,2021, 'Managing epidermolysis bullosa during the coronavirus pandemic: Experience and ideals', Clinics in Dermatology, 39, pp. 369 - 373, http://dx.doi.org/10.1016/j.clindermatol.2021.01.014
,2021, 'Over-expression of stromal periostin correlates with poor prognosis of cutaneous squamous cell carcinomas', Experimental Dermatology, 30, pp. 698 - 704, http://dx.doi.org/10.1111/exd.14281
,2021, 'Beyond the skin: Disease parameters in pemphigus', Italian Journal of Dermatology and Venereology, 156, pp. 147 - 150, http://dx.doi.org/10.23736/S2784-8671.21.06678-5
,2021, 'A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)', JAAD International, 2, pp. 134 - 152, http://dx.doi.org/10.1016/j.jdin.2020.12.007
,2021, 'Heralding change within dermatology: Response of the International Journal of Women's Dermatology (IJWD) to the twin pandemic of racism', International Journal of Women's Dermatology, 7, pp. 125 - 126, http://dx.doi.org/10.1016/j.ijwd.2021.03.008
,2021, 'Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis', Journal of Allergy and Clinical Immunology, 147, pp. 1107 - 1109.e2, http://dx.doi.org/10.1016/j.jaci.2020.09.021
,2021, 'The role of women as past and present advocates for vaccinations: Relevance in the COVID-19 setting', International Journal of Women's Dermatology, 7, pp. 228 - 229, http://dx.doi.org/10.1016/j.ijwd.2020.10.001
,2021, 'Obituary: Vale Robert Alan Briggaman MD 1934-2020', BRITISH JOURNAL OF DERMATOLOGY, 184, pp. 379 - 380, http://dx.doi.org/10.1111/bjd.19404
,2021, 'Authors' reply to the comment “Treatment considerations for patients with pemphigus during the COVID-19 pandemic”', Journal of the American Academy of Dermatology, 84, pp. e61 - e62, http://dx.doi.org/10.1016/j.jaad.2020.09.002
,2021, 'Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus', Dermatologic Therapy, 34, http://dx.doi.org/10.1111/dth.14675
,2021, 'Conducting dermatology clinical trials during the COVID-19 pandemic', Clinics in Dermatology, 39, pp. 104 - 106, http://dx.doi.org/10.1016/j.clindermatol.2020.12.019
,2021, 'Ectropion surgery might not be a long-term solution for harlequin ichthyosis', Dermatologic Therapy, 34, http://dx.doi.org/10.1111/dth.14646
,2021, '157 A comparison study of Outcome Measures for Epidermolysis Bullosa; Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)', Journal of Investigative Dermatology, 141, pp. S28 - S28, http://dx.doi.org/10.1016/j.jid.2021.02.177
,2021, '557 Assessment of skin of color and diversity and inclusion content published in the Journal of Investigative Dermatology: An analysis and call to action', Journal of Investigative Dermatology, 141, pp. S97 - S97, http://dx.doi.org/10.1016/j.jid.2021.02.584
,2021, '615 Efficacy and safety of Oleogel-S10 (birch triterpenes) for recessive dystrophic epidermolysis bullosa (RDEB): Results of 3 months double-blind treatment of the phase 3 study ‘EASE’', Journal of Investigative Dermatology, 141, pp. S107 - S107, http://dx.doi.org/10.1016/j.jid.2021.02.644
,2021, 'A dark lesion on an Indian Woman's vulva', International Journal of Women's Dermatology, 7, pp. 201 - 202, http://dx.doi.org/10.1016/j.ijwd.2021.02.004
,2021, 'Efficacité et innocuité de l’Oleogel-S10 (triterpènes de bouleau) dans l’épidermolyse bulleuse : résultats à 3 mois de l’étude de phase 3 « EASE » en double aveugle', Annales de Dermatologie et de Vénéréologie - FMC, 1, pp. A107 - A107, http://dx.doi.org/10.1016/j.fander.2021.09.525
,2021, 'Introduction and purpose: The House of Medicine & Dermatology.', Int J Womens Dermatol, 7, pp. 517 - 518, http://dx.doi.org/10.1016/j.ijwd.2021.09.005
,2020, 'Osteoporosis and bone health in autoimmune blistering skin disease—an evidenced based review', Journal of the European Academy of Dermatology and Venereology, 34, pp. 2745 - 2756, http://dx.doi.org/10.1111/jdv.16334
,2020, 'International collaboration', Journal of Dermatological Treatment, 31, pp. 757, http://dx.doi.org/10.1080/09546634.2020.1794290
,2020, 'A giant in dermatology has fallen: Robert Alan "Al'' Briggaman, MD IN MEMORY', JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 83, pp. E381 - E381, http://dx.doi.org/10.1016/j.jaad.2020.06.076
,2020, 'COVID-19 and immunosuppressive therapy in dermatology', Dermatologic Therapy, 33, http://dx.doi.org/10.1111/dth.14140
,2020, 'Dermatology and specialty rotations: COVID-19 may reemphasize the importance of internal medicine', Dermatologic Therapy, 33, http://dx.doi.org/10.1111/dth.13996
,2020, 'Financial burden of epidermolysis bullosa on patients in the United States', Pediatric Dermatology, 37, pp. 1198 - 1201, http://dx.doi.org/10.1111/pde.14340
,2020, 'Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology', Journal of the American Academy of Dermatology, 83, pp. 1315 - 1322, http://dx.doi.org/10.1016/j.jaad.2020.01.049
,2020, 'Role of music therapy in reducing the burden of dermatological diseases during COVID-19', Dermatologic Therapy, 33, http://dx.doi.org/10.1111/dth.14086
,2020, 'Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores', British Journal of Dermatology, 183, pp. 944 - 945, http://dx.doi.org/10.1111/bjd.19173
,2020, 'Treatment concerns for bullous pemphigoid in the COVID-19 pandemic era', Dermatologic Therapy, 33, http://dx.doi.org/10.1111/dth.13956
,